Qiming Venture Partners Weekly: Top 10 Portfolio Company Updates Vol. 03, Jan. 27, 2026
Join us in celebrating milestone moments for Qiming Venture Partners' portfolio companies
@author-1788515151757110
启明创投致力于成为中国优秀技术创业者们的首选投资机构
Join us in celebrating milestone moments for Qiming Venture Partners' portfolio companies
Build a shared framework for dialogue among industry, professional communities, and policymakers based on common understanding, driving the formation of foundational international norms of conduct.
Uncovering the Forces of Business Transformation Over the Next 3–5 Years
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
China's venture capital market has entered a recovery channel, buoyed by the flood of AI.
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
late-stage clinical biotech company
A global leader in innovative tumor immunotherapy
Qiming Venture Partners co-led Zhipu AI's Series B1 round in early 2022 — nearly a year before ChatGPT's release ignited the global large language model wave. It was this funding that enabled Zhipu AI to push through the R&D of its first 100-billion-parameter model, GLM. Qiming Venture Partners continued to back the company in its Series B2 and B4 rounds.
Qiming Venture Partners adheres to a "half-step ahead" investment methodology: positioning itself before a major wave coalesces into explicit consensus, yet not so early that it enters purely unconverged scientific exploration. This demands deep industry understanding from the firm and a powerful "radar" network to capture convergence signals.